Rhumbline Advisers Sage Therapeutics, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 86,086 shares of SAGE stock, worth $454,534. This represents 0.0% of its overall portfolio holdings.

Number of Shares
86,086
Previous 91,002 5.4%
Holding current value
$454,534
Previous $988,000 37.25%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$7.02 - $13.08 $34,510 - $64,301
-4,916 Reduced 5.4%
86,086 $620,000
Q2 2024

Aug 01, 2024
BUY
$10.58 - $17.9 $143,602 - $242,956
13,573 Added 17.53%
91,002 $988,000
Q1 2024

May 09, 2024
BUY
$18.62 - $26.95 $32,510 - $47,054
1,746 Added 2.31%
77,429 $1.45 Million
Q4 2023

Feb 08, 2024
SELL
$17.1 - $22.26 $6,173 - $8,035
-361 Reduced 0.47%
75,683 $1.64 Million
Q3 2023

Nov 09, 2023
BUY
$16.75 - $48.98 $13,132 - $38,400
784 Added 1.04%
76,044 $1.56 Million
Q2 2023

Aug 08, 2023
SELL
$40.65 - $59.54 $432,231 - $633,088
-10,633 Reduced 12.38%
75,260 $3.54 Million
Q1 2023

May 11, 2023
BUY
$37.27 - $46.57 $69,284 - $86,573
1,859 Added 2.21%
85,893 $3.6 Million
Q4 2022

Feb 14, 2023
BUY
$32.2 - $43.61 $46,368 - $62,798
1,440 Added 1.74%
84,034 $3.21 Million
Q3 2022

Nov 10, 2022
BUY
$32.28 - $43.27 $174,473 - $233,874
5,405 Added 7.0%
82,594 $3.23 Million
Q2 2022

Aug 11, 2022
BUY
$27.52 - $37.99 $959,484 - $1.32 Million
34,865 Added 82.38%
77,189 $2.49 Million
Q1 2022

May 12, 2022
SELL
$30.71 - $45.71 $169,642 - $252,502
-5,524 Reduced 11.54%
42,324 $1.4 Million
Q4 2021

Feb 10, 2022
BUY
$37.06 - $47.11 $3,409 - $4,334
92 Added 0.19%
47,848 $2.04 Million
Q3 2021

Nov 12, 2021
SELL
$40.26 - $57.37 $172,514 - $245,830
-4,285 Reduced 8.23%
47,756 $2.12 Million
Q2 2021

Aug 05, 2021
SELL
$54.88 - $79.29 $186,811 - $269,903
-3,404 Reduced 6.14%
52,041 $2.96 Million
Q1 2021

May 06, 2021
SELL
$70.65 - $96.76 $150,484 - $206,098
-2,130 Reduced 3.7%
55,445 $4.15 Million
Q4 2020

Feb 10, 2021
BUY
$58.41 - $89.06 $58,994 - $89,950
1,010 Added 1.79%
57,575 $4.98 Million
Q3 2020

Nov 12, 2020
SELL
$41.13 - $62.45 $41,541 - $63,074
-1,010 Reduced 1.75%
56,565 $3.46 Million
Q2 2020

Aug 13, 2020
BUY
$25.95 - $43.15 $164,808 - $274,045
6,351 Added 12.4%
57,575 $2.39 Million
Q1 2020

May 06, 2020
SELL
$26.15 - $77.24 $18,723 - $55,303
-716 Reduced 1.38%
51,224 $1.47 Million
Q4 2019

Feb 05, 2020
BUY
$60.18 - $154.77 $70,530 - $181,390
1,172 Added 2.31%
51,940 $3.75 Million
Q3 2019

Oct 23, 2019
SELL
$140.29 - $189.96 $34,230 - $46,350
-244 Reduced 0.48%
50,768 $7.12 Million
Q2 2019

Aug 14, 2019
BUY
$157.85 - $183.09 $367,474 - $426,233
2,328 Added 4.78%
51,012 $9.34 Million
Q1 2019

May 01, 2019
BUY
$89.33 - $163.65 $158,739 - $290,806
1,777 Added 3.79%
48,684 $7.74 Million
Q4 2018

Jan 31, 2019
SELL
$81.94 - $139.71 $117,174 - $199,785
-1,430 Reduced 2.96%
46,907 $4.49 Million
Q3 2018

Nov 07, 2018
SELL
$138.11 - $169.04 $127,751 - $156,362
-925 Reduced 1.88%
48,337 $6.83 Million
Q2 2018

Aug 06, 2018
BUY
$140.36 - $175.76 $1.17 Million - $1.46 Million
8,307 Added 20.28%
49,262 $7.71 Million
Q1 2018

May 02, 2018
BUY
$152.15 - $192.33 $369,572 - $467,169
2,429 Added 6.3%
40,955 $6.6 Million
Q4 2017

Feb 09, 2018
SELL
$60.72 - $167.34 $233,468 - $643,422
-3,845 Reduced 9.07%
38,526 $6.35 Million
Q3 2017

Nov 06, 2017
BUY
$61.4 - $88.52 $2.6 Million - $3.75 Million
42,371
42,371 $2.64 Million

Others Institutions Holding SAGE

# of Institutions
198
Shares Held
46.5M
Call Options Held
402K
Put Options Held
209K
View Full List

About Sage Therapeutics, Inc.

SAGE Quotes by TradingView
  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $314M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email